Charg­ing at block­buster Ad­vair, No­var­tis boasts topline vic­to­ries for asth­ma drugs in twin PhI­II stud­ies

In a bit of a Rus­sain nest­ing doll mo­ment, No­var­tis says that its po­ten­tial block­buster asth­ma drug has beat an­oth­er treat­ment from its port­fo­lio, which …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.